TransMedics Group (NASDAQ:TMDX) Issues Quarterly Earnings Results

TransMedics Group (NASDAQ:TMDX) announced its quarterly earnings results on Tuesday. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32), FiscalAI reports. The firm had revenue of $173.93 million for the quarter, compared to analyst estimates of $174.48 million. TransMedics Group had a return on equity of 30.17% and a net margin of 31.43%.

TransMedics Group Stock Down 2.2%

TMDX traded down $2.15 on Tuesday, reaching $94.93. The company’s stock had a trading volume of 1,693,131 shares, compared to its average volume of 888,566. The stock has a market cap of $3.28 billion, a price-to-earnings ratio of 19.37 and a beta of 2.07. TransMedics Group has a 1 year low of $91.01 and a 1 year high of $156.00. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59. The business’s 50 day moving average is $117.36 and its 200 day moving average is $126.08.

Insider Transactions at TransMedics Group

In related news, insider Anil P. Ranganath sold 864 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $120,199.68. Following the completion of the transaction, the insider owned 13,091 shares of the company’s stock, valued at approximately $1,821,219.92. This represents a 6.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Stephanie Lovell sold 1,193 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $149.62, for a total value of $178,496.66. Following the completion of the transaction, the director directly owned 2,866 shares of the company’s stock, valued at $428,810.92. This represents a 29.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 16,205 shares of company stock valued at $2,353,002 in the last three months. 6.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in TransMedics Group by 11.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after buying an additional 113,817 shares during the last quarter. Two Sigma Investments LP lifted its holdings in TransMedics Group by 54.2% during the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after buying an additional 223,409 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in TransMedics Group by 43.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock worth $69,338,000 after buying an additional 171,810 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in TransMedics Group by 8.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 489,710 shares of the company’s stock worth $59,574,000 after buying an additional 38,717 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

TMDX has been the subject of several research analyst reports. Wall Street Zen lowered TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Needham & Company LLC upped their target price on TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Stifel Nicolaus upped their target price on TransMedics Group from $115.00 to $130.00 and gave the stock a “hold” rating in a research report on Monday, March 9th. TD Cowen reaffirmed a “buy” rating on shares of TransMedics Group in a research report on Monday, March 16th. Finally, JPMorgan Chase & Co. upped their target price on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $152.33.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.